Stay updated on Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.

Latest updates to the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page
- Check2 days agoChange DetectedThe page revision was updated from v3.5.3 to v3.5.4, indicating a deployed update to the ClinicalTrials.gov entry.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page’s footer revision label has been updated from v3.5.2 to v3.5.3, reflecting a site software/version change rather than a change to the clinical trial record.SummaryDifference0.0%

- Check31 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check53 days agoChange DetectedAdrenal cortex carcinoma was added as a lay term for Adrenocortical Carcinoma in the Conditions section.SummaryDifference0.0%

- Check60 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check74 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3; the page now shows Revision: v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.